Menu
Search
|

Menu

Close
X

Pieris Pharmaceuticals Inc PIRS.OQ (NASDAQ Stock Exchange Capital Market)

5.20 USD
-0.10 (-1.89%)
As of Oct 19
chart
Previous Close 5.30
Open 5.29
Volume 67,007
3m Avg Volume 117,929
Today’s High 5.42
Today’s Low 5.12
52 Week High 9.69
52 Week Low 4.44
Shares Outstanding (mil) 44.31
Market Capitalization (mil) 276.04
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
16
FY17
25
FY16
6
FY15
3
EPS (USD)
FY18
-0.178
FY17
-0.410
FY16
-0.545
FY15
-0.420
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
41.16
5.83
Price to Book (MRQ)
vs sector
29.26
4.89
Price to Cash Flow (TTM)
vs sector
--
22.92
Total Debt to Equity (MRQ)
vs sector
0.00
17.18
LT Debt to Equity (MRQ)
vs sector
0.00
12.76
Return on Investment (TTM)
vs sector
-55.96
14.27
Return on Equity (TTM)
vs sector
-132.26
15.99

EXECUTIVE LEADERSHIP

James Geraghty
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Stephen Yoder
President, Chief Executive Officer, Director, Since 2014
Salary: $266,222.00
Bonus: $54,455.00
Lance Thibault
Acting Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Claude Knopf
Senior Vice President, Chief Business Officer, Since 2016
Salary: --
Bonus: --
Louis Matis
Senior Vice President and Chief Development Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

255 State St Fl 9
BOSTON   MA   02109-2615

Phone: +1857.2468998

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

SPONSORED STORIES